Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy

BACKGROUND AND AIMS: Patients affected by moderate-to-severe Ulcerative Colitis (UC) demand a challenging management. Small molecules, administrated as oral agents, have the ambition of overcoming the limitations of the biologic agents (ie, parenteral administration, rapidity of action, primary and...

Descripción completa

Detalles Bibliográficos
Autores principales: Dal Buono, Arianna, Gabbiadini, Roberto, Solitano, Virginia, Vespa, Edoardo, Parigi, Tommaso Lorenzo, Repici, Alessandro, Spinelli, Antonino, Armuzzi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329679/
https://www.ncbi.nlm.nih.gov/pubmed/35909812
http://dx.doi.org/10.2147/CEG.S350193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329679/
https://www.ncbi.nlm.nih.gov/pubmed/35909812
http://dx.doi.org/10.2147/CEG.S350193

Ejemplares similares